I suspect this is where a new way of doing things, which is already happening in oncology and other areas, called precision medicine could come into play.
So rather than defining disease by its phenotypic/syndromic features, it is defined by its molecular features. What this would mean, is that instead of having to do a separate trial for each of 100+ syndromes, you just do one trial incorporating any patient who has a genetic alteration resulting in IGF-1 and pERK dysregulation for example, or whatever the molecular target of 2591 is deemed to be.
Now this is all more easily said than done and is a nascent field, but it is already happening and with the exponential advances in the field of genomics I think provides a way forward for phenotypically heterogeneous disease.
- Forums
- ASX - By Stock
- NEU
- Moonsoon Briefing Thurs 20 April
Moonsoon Briefing Thurs 20 April, page-66
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.12 |
Change
-0.270(1.39%) |
Mkt cap ! $2.440B |
Open | High | Low | Value | Volume |
$19.55 | $19.65 | $18.88 | $4.661M | 243.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 758 | $19.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.12 | 1 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 720 | 19.110 |
9 | 1623 | 19.100 |
8 | 514 | 19.090 |
5 | 1113 | 19.080 |
5 | 484 | 19.070 |
Price($) | Vol. | No. |
---|---|---|
19.120 | 56 | 6 |
19.130 | 971 | 18 |
19.140 | 516 | 8 |
19.150 | 11318 | 7 |
19.160 | 1396 | 7 |
Last trade - 13.44pm 31/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online